Silexion Therapeutics Corp
Filed Oct 9, 2024.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Oct 9, 2024
SLXN$0.15+1.0%Stored close · as of Nov 6, 2026
Contents
Balance Sheets
| Note | December 31,2023 | December 31,2022 | |
|---|---|---|---|
| U.S. Dollars | |||
| Assets | |||
| ASSETS: | |||
| Cash and cash equivalents | 108,278 | 59,714 | |
| Investments held in Trust Account | 5,697,632 | 116,692,038 | |
| Prepaid expenses | 28,305 | 43,853 | |
| TOTAL ASSETS | 5,834,215 | 116,795,605 | |
| Liabilities and shares subject to possible redemptionnet of capital deficiency | |||
| LIABILITIES: | |||
| Accrued expenses | 115,560 | 86,688 | |
| Related party | 4 | 2,861,000 | 1,190,000 |
| Private warrant liability | 8,531 | 29,640 | |
| TOTAL LIABILITIES | 2,985,091 | 1,306,328 | |
| COMMITMENTS AND CONTINGENCIES | 5 | — | — |
| CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION: 515,019 and 11,500,000 shares at redemption value $11.06 and $10.15 as of December 31, 2023 and 2022, respectively | 5,697,632 | 116,692,038 | |
| CAPITAL DEFICIENCY: | 7 | ||
| Class A Ordinary Shares, $0.0001 par value; 500,000,000 shares authorized, 3,354,999 and 480,000 issued and outstanding (excluding 515,019 and 11,500,000 shares subject to possible redemption) as of December 31, 2023 and 2022, respectively; | 336 | 48 | |
| Class B Ordinary Shares, $0.0001 par value; 50,000,000 shares authorized, 1 and 2,875,000 issued and outstanding as of December 31, 2023 and 2022, respectively; | * | 288 | |
| Preferred Shares, $0.0001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022. | — | — | |
| Additional paid-in capital | — | — | |
| Accumulated deficit | (2,848,844) | (1,203,097) | |
| TOTAL CAPITAL DEFICIENCY | (2,848,508) | (1,202,761) | |
| TOTAL LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY | 5,834,215 | 116,795,605 | |
| * | Less than one US dollar. |
|---|
The accompanying notes are an integral part of these financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.